{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05868629",
            "orgStudyIdInfo": {
                "id": "CDRB436IIC01"
            },
            "organization": {
                "fullName": "Novartis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors",
            "officialTitle": "Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "clinical-study-to-further-evaluate-the-efficacy-of-dabrafenib-plus-trametinib-in-patients-with-rare-braf-mutation-positive-unresectable-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-29",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02-29",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-11",
            "studyFirstSubmitQcDate": "2023-05-11",
            "studyFirstPostDateStruct": {
                "date": "2023-05-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Novartis Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (6 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation."
        },
        "conditionsModule": {
            "conditions": [
                "Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors"
            ],
            "keywords": [
                "BRAF",
                "v-raf murine sarcoma viral oncogene homolog B1",
                "dabrafenib",
                "trametinib",
                "tumor agnostic"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "dabrafenib plus trametinib",
                    "description": "patients treated with dabrafenib and trametinib",
                    "interventionNames": [
                        "Other: Non-investigational"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Non-investigational",
                    "description": "Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program",
                    "armGroupLabels": [
                        "dabrafenib plus trametinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "Proportion of study participants with a best overall confirmed Complete Response (CR) or Partial Response (PR) by independent central review according to RECIST v1.1 or other relevant response criteria.",
                    "timeFrame": "Approximately 4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of response (DOR)",
                    "description": "Defined as time from the onset of tumor response until the date of the first documented progressive disease (PD) or death due to any cause.",
                    "timeFrame": "Approximately 4 years"
                },
                {
                    "measure": "Clinical benefit rate (CBR)",
                    "description": "Defined as the proportion of study participants with a best overall response of CR, PR or stable disease (SD), lasting as per independent central review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST v1.1. or other relevant response criteria.",
                    "timeFrame": "Approximately 4 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Study participant with a BRAF V600E mutation-positive solid tumor as confirmed by a local laboratory test;\n* At least 1 measurable lesion as defined by RECIST v1.1 per local review;\n* Study participant previously not treated with dabrafenib and/or trametinib. Study participants who received dabrafenib and trametinib in the past for the treatment of other malignancies are eligible if treatment has been discontinued for greater than 1 year;\n* Ability to provide scans for central imaging review\n\nExclusion Criteria:\n\n* Those with the following tumor types: melanoma, NSCLC, ATC, BTC, glioma and CRC;\n* Study participants who have contraindication to receive dabrafenib and/ or trametinib according to the local label;",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Study participants diagnosed with a rare BRAF V600E mutation-positive unresectable or metastatic solid tumor, 6 years and older excluding patients with melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Anaplastic Thyroid Cancer, Biliary Tract Cancer and glioma, who will be treated with dabrafenib and trametinib.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "1-888-669-6682",
                    "email": "novartis.email@novartis.com"
                },
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "affiliation": "Novartis Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Duke Clinical Research Institute .",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27704",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Emily Bolch",
                            "role": "CONTACT",
                            "email": "emily.bolch@duke.edu"
                        },
                        {
                            "name": "John Strickler",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M218495",
                    "name": "Trametinib",
                    "relevance": "LOW"
                },
                {
                    "id": "M217673",
                    "name": "Dabrafenib",
                    "relevance": "LOW"
                },
                {
                    "id": "M1804",
                    "name": "Carbamide Peroxide",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}